EVOLUS INC (EOLS) Stock Price, Forecast & Analysis
NASDAQ:EOLS • US30052C1071
EOLS Key Statistics, Chart & Performance
The current stock price of EOLS is 4.37 USD. In the past month the price decreased by -13.98%. In the past year, price decreased by -68.76%.
EOLS Technical Analysis
EOLS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EOLS. EOLS may be in some trouble as it scores bad on both profitability and health.
EOLS Financial Highlights
Over the last trailing twelve months EOLS reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by -9.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.74% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
EOLS Forecast & Estimates
13 analysts have analysed EOLS and the average price target is 16.83 USD. This implies a price increase of 285.13% is expected in the next year compared to the current price of 4.37.
For the next year, analysts expect an EPS growth of -74.42% and a revenue growth 11.49% for EOLS
EOLS Ownership
EOLS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.08 | 967.332B | ||
| JNJ | JOHNSON & JOHNSON | 20.81 | 594.88B | ||
| MRK | MERCK & CO. INC. | 22.6 | 302.459B | ||
| PFE | PFIZER INC | 8.87 | 152.718B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.97 | 122.756B | ||
| ZTS | ZOETIS INC | 18.75 | 56.091B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.039B | ||
| VTRS | VIATRIS INC | 6.29 | 18.405B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.89 | 12.521B | ||
| AXSM | AXSOME THERAPEUTICS INC | 224.33 | 9.385B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EOLS
Company Profile
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 329 full-time employees. The company went IPO on 2018-02-08. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Company Info
EVOLUS INC
520 Newport Center Dr Ste 1200
Newport Beach CALIFORNIA 92660 US
CEO: David Moatazedi
Employees: 329
Phone: 19492844555
EVOLUS INC / EOLS FAQ
What does EVOLUS INC do?
Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 329 full-time employees. The company went IPO on 2018-02-08. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
What is the stock price of EVOLUS INC today?
The current stock price of EOLS is 4.37 USD. The price decreased by -1.13% in the last trading session.
Does EVOLUS INC pay dividends?
EOLS does not pay a dividend.
What is the ChartMill technical and fundamental rating of EOLS stock?
EOLS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is EVOLUS INC (EOLS) stock traded?
EOLS stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for EVOLUS INC?
The Revenue of EVOLUS INC (EOLS) is expected to grow by 11.49% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is EVOLUS INC worth?
EVOLUS INC (EOLS) has a market capitalization of 283.26M USD. This makes EOLS a Micro Cap stock.